Summary.-A comparative study of the effects of BCG, Micrococcus lysodeikticus, and a series of structurally related polysaccharides (complement triggers) on the nonspecific and specific immune resistance against L1210 lymphoid leukaemia was carried out and commented on. In contrast with authors of earlier reports, we were unable to generate any effective non-specific or specific immunotherapy after the graft of 104 leukaemic cells to 8-10-week-old CDF1 mice. However, when mice were prevaccinated with irradiated (8 krad X-rays) cultured cells combined with 1 mg of bacterium or polysaccharide one month before grafting 10 cells, they were given an immunoprotection that was more pronounced with the i.p. than with the i.v. route. Prevaccinated mice were afforded a stronger immunoprotection when boosted repeatedly with 1mg injections of bacterium or polysaccharide after tumour challenge.
IT is now clearly established that the administration, before the graft of a tumour, of adjuvants (Old et al., 1959) or of irradiated tumour cells (Glynn et al., 1963) can inhibit the growth of transplantable tumours in rodents. Mathe et al. (1969) have introduced the concept of active anti-tumour immunotherapy. They demonstrated conclusively that active immunotherapy by BCG and Corynebacterium parvum combined with irradiated leukaemic cells may strongly control the proliferation of L 1210 leukaemia. Numerous further reports have described the protecting effect of BCG and anaerobic C. parvum against many syngeneic mouse tumours (see Milas & Scott, 1978; Mitchell, 1976) . Although adjuvants such as BCG may exert various biological activities, like, for instance, T cell adjuvant (Miller et al., 1] 973), induction of natural killer cells (Seth et al., 1976) , increased lymphocyte trapping (Zatz, 1976) and induction of T-cell-independent B responses (Sultzer, 1978) , the general use of BCG has many disadvantages: BCG can cause ulceration, pyrexia, liverfunction abnormalities, tuberculosis and, in a few reported cases, death or even enhancement of tumour growth (Mansell & Krementz, 1973; Spark et al., 1973; Hunt et al., 1973) .
Therefore, it was important to define the "active substance" of the bacterium, or to search for new compounds with similar biological properties. There is increasing evidence that an effective antineoplastic immune reactivity is induced by activated macrophages and phagocytes (Evans & Alexander, 1972) that express membrane receptors for the complement component C3 (Hainz, 1968) .
Complement activation is a very important step in inflammation that switches on multiple biological processes such as B-cell proliferation, macrophage activation (Bianco et al.,1976) and attraction of polynucleated cells to the inflammation site (WVard, 1967) . These phenomena occur after binding of the activated compounds on specific membrane receptors (C3b or C3d) and are non-lytic to the affected cell.
Especially for the macrophage, the complement-induced signal leads to activation followed by extrusion of the lysosomal content into the surrounding mediuin (Schorlemmer et al., 1976) . We have previously demonstrated that the Gram-positive but non-pathogenic bacterium Micrococcus lysodeikticus (ATCC 4698) is able to activate complement by the alternative pathway (Verloes et al., 1977) . In this study, we investigate the therapeutic values of this bacterium with the activity generated by structurally related complement-triggering polysaccharides and BCG. Many of these polysaccharides are active on a wide variety of rodent tumours, but this study aims at comparing their activity on a transplantable leukaemia, an often-solicited model for preclinical chemotherapeutic drug screening (Geran et al., 1972 Bacillus Calmette-Gue'rin.-100 mg vials of lyophilized Bacillus Calmette-Gue'rin for scarification (BCG-SP) were purchased from the Pasteur Institute, Brussels.
After recombination with the appropriate diluent and further dilution in Hank's balanced salt solution, the suspension was kept at 4°C and used within 2 weeks.
Cell wall of ML, cell-wall-conjugated chitin and chitin.-These were prepared as described earlier (Verloes et al., 1976 Dextran sulphate (sodium salt).-The material used was a polysaccharide with a mol. wt of approximately 500,000, and was purchased from Pharmacia Fine Chemicals (Lot No. 7126) .
Quantitative agglutination analyses.-These were carried out in U-shaped wells of Linbro agglutination plates. 0 05 ml of the antiserum was mixed with 0-05 ml of PBS and consecutive two-fold dilutions were made. After a preincubation of' 30 min at 37°C, 0-05 ml of the ML suspension (2 mg/ml) were added and the agglutination was scored after 2 h at 37°C and expressed in log2 units.
Animals.-Female CDF1 (H2d) hybrid [female BALB/c (H2d) x male DBA/2 (H2d)] F1 animals were purchased from Charles River Breeding Laboratories, Calco, Italy. Those mice were stored for at least 3 weeks in an isolation room and were used before they were 10 weeks old. Animals weighing 19-23 g were used.
Tumour.-L1210 lymphoid leukaemia was originally obtained from Mr I. Wodinsky (Arthur D. Little, Inc., Cambridge, Mass., U.S.A.). This tumour was maintained in DBA/2 mice by weekly i.p. inoculation. L1210 cells were aspirated from DBA/2 mice and a suspension was made in Hank's balanced salt solution: 104 cells in 0.1 ml solution were injected i.p. to obtain the ascitic form of leukaemia or i.v. to obtain the blood form of the leukaemia. Animals were randomized into test and control groups. Ten to 20 mice were used for each experiment.
Mean survival time (MST) ± the standard deviation of treated and control mice as well as the doses and timing of each experiment are specified in the tables. Mice that were tumour-free on the 90th day after tumour grafting were considered as long-term survivors and were eliminated from calculation of the mean survival time and the standard deviation. The ratio of MST of treated mice to controls is expressed. Although it was often difficult to support considerable increases in MST of treated mice over the controls by Student's t test (because of high standard deviations), we considered the percentage of long-term survivors to be the best evaluation. However, when mouse sera taken from the retro-orbital plexus on Day 25 were analysed, we found positive agglutination patterns with 2 mg/ml micrococcus suspension for micrococcus (log2 = 6-42 ± 1.86), zymosan A (log2 = 1-9 ± 2.25), inulin (log2 2-05 ± 1.42), chitin (log2 1-5 + 0 87) and cell-wall-conjugated chitin (log _ 0-29 + 0-39).
However positive agglutination patterns due to cross-reactions of immunoglobulins with micrococcus epitopes were never detected in sera of BCG or dextransulphate-treated mice. (Johnson et al., 1975) or BCG (Mathe et al., 1969) were successfully used to reinforce the immunological potential of mice bearing transplantable tumours. Macrophages and phagocytes are mediators of immune processes, and also have a strong anti-neoplastic cytotoxic potential (Evans & Alexander, 1972) . Since those particular cell types are known to be activated through the serum complement system (Bianco, et al.,1976) Furthermore, if activation of macrophages by BCG requires a T-cell adjuvant effect, as C. parvum does (Sljivic & Watson, 1977) , it is worth mentioning that BCG adjuvant activity becomes significant only after 2 weeks (Mathe et al., 1973) . This is probably too long a lag for immunotherapy to be effective against neoplasms that kill untreated mice 10 days after tumour grafting.
However, when CDF1 mice were prevaccinated by grafting 107 irradiated cultured L1210 cells and by injecting i.v. or i.p. 1 mg of different agents 1 month before tumour grafting, they were provided with an effective anti-tumour immune resistance against 104 leukaemic cells grafted by the vaccination route. When prevaccinated mice (107 irradiated cultured cells + 1 mg bacterium or polysaccharide) received 1 month later a transplant of 104 leukaemic cells, they showed a better immune resistance when boosted on Days 4, 7, 10 and 1 3 with 1 mg of bacterium or polysaccharide than when rechallenged with 107 irradiated L1210 cells and complement trigger (Day 1) and boosted on Days 4, 7, 10 and 13 with complement activators only.
According to the immunostimulation theory of Prehn (1972) a minimal immune response to tumour cells accelerates tumour growth, whereas a vigoronsreaction is cytotoxic. Consequently, the challenge of mi.ce w1ith high doses of tumour cells may weaken the effectiveness of immune-bell proliferation from the day of tumour grafting. High doses of rapidly proliferating leukaemia cells may soon exceed the immune capacity of mice and dramatically counterbalance the immune-effector-cell: tumour-cell ratio. However, secondary immune responses of mice sensitized before tumour grafting may yield stronger and earlier immune responsiveness leading to effective immunotherapy, as illustrated in Table II. The i.p. route was found to be more effective than the i.v.; it increased MST over controls and induced survivors to Day 90 after tumour grafting. This is not surprising, since intratumoral treatments have yielded optimal results in other tumour systems also (Pinsky et al., 1973; Zbar et al., 1971) . Since L1210 leukaemia kills untreated mice early and with small standard deviations, it offers the most highly recommended and reliable animal tumour model that allows activity prediction against human leukaemia (Geran et al., 1972) after drug screening, immunoprophylactic or chemo-immunotherapeutic studies. However, its usefulness for pure immunotherapeutic investigations is questionable. Clearly, clinical immunotherapy requires more fundamental knowledge of immunological mechanisms and optimal treatment parameters obtained from adequate preclinical animal models, to be successful against human neoplasms.
